Korea's Celltrion Cuts Deal With Jordan-based Hikma To Sell Its Biosimilars In The Middle East, Africa
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Days after finalizing a deal to sell biosimilar therapeutic antibodies in Israel, Korea's Celltrion has signed a similar agreement with Jordan-based Hikma Pharmaceuticals to market the products across 17 Middle East and Northwestern African countries
You may also be interested in...
Jordan's Hikma Sees Double-digit Sales Growth In First Half, Continues Aggressive M&A Expansion In Middle East
Hikma, one of the fastest growing multinational pharmaceutical companies, reported group revenue Aug. 26 up 11.3 percent year-on-year for the first half of 2010. Diversified among branded, generic and injectables, the Jordanian drug maker attributed the growth to strong generics sales in the U.S
Jordan's Hikma Sees Double-digit Sales Growth In First Half, Continues Aggressive M&A Expansion In Middle East
Hikma, one of the fastest growing multinational pharmaceutical companies, reported group revenue Aug. 26 up 11.3 percent year-on-year for the first half of 2010. Diversified among branded, generic and injectables, the Jordanian drug maker attributed the growth to strong generics sales in the U.S
Korea's Celltrion Banks On Increasing Profits Resulting From New Focus On Biosimilars
SEOUL - Biopharmaceutical firm Celltrion posted a record performance in the most recent quarter due to the company's shift in focus from contract manufacturing to producing biosimilars